Biosimilars Commercialization: Four Lessons Learned from Adalimumab

As manufacturers seek to capitalize on blockbuster biologic LOEs in the coming years, the adalimumab market has proven that a successful biosimilar launch is not guaranteed.  Biosimilars began entering the market about 18 months ago. Despite early access being achieved by leading competitors, Humira’s position in the market and likely portfolio-level rebating were able to […]